Aura Biosciences/$AURA
1D1W1MYTD1Y5YMAX
Capital at risk
About Aura Biosciences
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.
- Ticker
- $AURA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 113
- Headquarters
- Boston, United States
- Website
- www.aurabiosciences.com
Aura Biosciences Metrics
BasicAdvanced
$727M
-
-$1.77
0.40
-
Price and volume
Market cap
$727M
Beta
0.4
52-week high
$9.54
52-week low
$4.73
Average daily volume
750K
Financial strength
Current ratio
16.821
Quick ratio
16.646
Long term debt to equity
0.042
Total debt to equity
0.053
Profitability
EBITDA (TTM)
-136.992
Effective tax rate (TTM)
-0.06%
Management effectiveness
Return on assets (TTM)
-31.24%
Return on equity (TTM)
-53.49%
Valuation
Price to book
2.3
Price to tangible book (TTM)
2.3
Price to free cash flow (TTM)
-5.013
Free cash flow yield (TTM)
-19.95%
Free cash flow per share (TTM)
-1.398
Growth
Earnings per share change (TTM)
-9.17%
3-year earnings per share growth (CAGR)
-3.83%
What the Analysts think about Aura Biosciences
Analyst ratings (Buy, Hold, Sell) for Aura Biosciences stock.
Analyst projections of the future price of Aura Biosciences stock.
Bulls say / Bears say
Aura completed enrollment in the 108-patient Phase 3 CoMpass trial ahead of target, and the study is being conducted under an FDA Special Protocol Assessment, improving regulatory alignment for a potential BLA. (Aura Biosciences)
The company reported $323.8 million in cash, cash equivalents and marketable securities as of June 30, 2026, with expected funding into the first half of 2029. This materially lowers near-term financing risk while Aura advances Phase 3 and prepares for potential commercialization. (Aura Biosciences)
Interim NMIBC data showed an 81% objective response rate and 69% complete-response rate at three months among intermediate-risk patients, with all evaluable patients reaching nine or twelve months remaining disease-free and treatment-related adverse events limited to Grade 1. (Aura Biosciences)
Topline data from the registration-enabling Phase 3 CoMpass trial are not expected until the second half of 2027, leaving investors exposed to a prolonged, binary clinical-risk period without a near-term efficacy catalyst. (Aura Biosciences)
Aura remains heavily loss-making: Q2 2026 net loss was $45.6 million, while R&D and G&A expenses rose to $30.7 million and $17.3 million, respectively. The company also expects $2.9–$3.2 million of restructuring charges following a workforce reduction of approximately 20%. (Aura Biosciences)
The strategic deprioritization of the NMIBC program reduces pipeline diversification and concentrates value creation on ocular oncology and bel-sar’s Phase 3 outcome, despite encouraging but still small-sample bladder-cancer data. (Aura Biosciences)
Data summarised monthly by Lightyear AI. Last updated on 10 Sept 2026.
Aura Biosciences Financial Performance
Revenues and expenses
Aura Biosciences Earnings Performance
Company profitability
Upcoming events
No upcoming events
Aura Biosciences News
AllArticlesVideos
Funds containing Aura Biosciences
AllUSDGBPEUR
Fund name | Fund size | $AURA weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.05% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.05% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.